Phenotyping methods for determining HIV tropism and applications in clinical settings

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 463-469

  Raymond, Stéphanie ^a,b,c   Delobel, Pierre ^a,b,c   Izopet, Jacques ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

Author keywords

CCR5; coreceptor; CXCR4; HIV tropism; phenotypic assay

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; RESTRICTION ENDONUCLEASE;

CD4+ T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PYROSEQUENCING; RESTRICTION MAPPING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRAL TROPISM; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

HIV; HIV INFECTIONS; HUMANS; PHENOTYPE; VIRAL TROPISM; VIROLOGY; VIRUS CULTIVATION;

EID: 84865661595     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356f6d7     Document Type: Review

References (62)

1. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previouslytreated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
2. Kuhmann SE, Hartley O. Targeting chemokine receptors in HIV: A statusreport. Annu Rev Pharmacol Toxicol 2008; 48:425-461.
3. Tsibris AMN, Kuritzkes DR. Chemokine antagonists as therapeutics: Focus onHIV-1. Annu Rev Med 2007; 58:445-459.
4. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4 cells is mediatedby the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
5. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: FunctionalcDNA cloning of a seven-transmembrane, G protein-coupled receptor.Science 1996; 272:872-877.
6. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-666.
7. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66:1354-1360.
8. Tersmette M, Gruters RA, de Wolf F, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989; 63:2118-2125.
9. Tersmette M, de Goede RE, Al BJ, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988; 62:2026-2032.
10. Karlsson A, Parsmyr K, Sandstróm E, et al. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994; 32:364-370.
11. Koot M, Vos AH, Keet RP, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992; 6:49-54.
12. Princen K, Hatse S, Vermeire K, et al. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level. AIDS Res Hum Retroviruses 2003; 19:1135- 1139.
13. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002; 99:16249-16254.
14. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 2005; 18:9-15.
15. Visseaux B, Hurtado-Nedelec M, Charpentier C, et al. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: Development of a new genotypic tool. J Infect Dis 2012; 205:111-120.
16. In this article, the authors describe an HIV-2 tropism phenotypic assay and identify genotypic determinants allowing the prediction of HIV-2 coreceptor usage.
17. Gonzalez-Serna A, Leal M, Genebat M, et al. TROCAI (tropism coreceptor assay information): A new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J Clin Microbiol 2010; 48:4453-4458.
18. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-575.
19. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.
20. Su Z, Gulick RM, Krambrink A, et al. Response to vicriviroc in treatmentexperienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009; 200:1724-1728.
21. Raymond S Delobel P Mavigner M et al. Development performance of a New Recombinant Virus Phenotypic Entry Assay To Determine HIV-1 Coreceptor Usage. J Clin Virol 2010; 47126-130.
22. Saliou A, Delobel P, Dubois M, et al. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 2011; 55:2831-2836. This article shows that the TTT and Trofile phenotypic assays correlate well with ultra-deep pyrosequencing for determining HIV-1 coreceptor usage.
23. González N, Pérez-Olmeda M, Mateos E, et al. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother 2010; 65:2493-2501.
24. Van Baelen K, Vandenbroucke I, Rondelez E, et al. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. J Virol Methods 2007; 146:61-73.
25. Hamy F, Garcia O, Klimkait T. Coreceptor tropism of HIV in clinical samples dissected by rPhenotyping. In: 4th IAS Conference, Sydney, Australia; 2007 July 22-25.
26. Hamy F, Vidal V, Hubert S, et al. (last). Development of a new hybridizationbased Genosorting' method for highly sensitive determination of HIV coreceptor tropism. In: 3rd International Workshop on Targeting HIV Entry, Washington, DC; 2007 December 7-9.
27. Coakley E Reeves JD Huang W et al. Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MTassays Antimicrob Agents Chemother 2009 534686-4693
28. Westby M Lewis M Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected atients following treatment with the CCR5 antagonist maraviroc is from a Pretreatment CXCR4-using Virus Reservoir. J Virol 2006; 804909-4920.
29. Archer J, Braverman MS, Taillon BE, et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009; 23:1209-1218.
30. Tsibris AM, Korber B, Arnaout R, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PloS One 2009; 4:e5683.
31. Swenson LC, Mo T, Dong WW, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: A reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011; 53:732-742
32. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviralnaive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-813.
33. Heera J, Harrigan PR, Lewis M et al. Predicting maraviroc responses according to number or percentage of X4-using virus among treatment-experienced patients. In: 18th Conference on Retroviruses and Opportunistic infections; Boston, MA, USA; 2011 27 February to 3 March. This study shows that thresholds of either 2% relative CXCR4-using virus or 3.7 log copies/mL absolute CXCR4-using virus predicted maraviroc response similarly among treatment experienced patients.
34. This article analyzes several tropism assays and reports a bettercorrelation between virological response to short-term maraviroc monotherapyand a pyrosequencing cutoff for X4-tropic strains of 2% Pppp
35. Gonzalez-Serna A, McGovern RA, Harrigan PR, et al. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods. AntimicrobAgents Chemother 2012; 56:1202-1207
36. Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl JMed 2008; 359:1965-1966.
37. Garrido C, Roulet V, Chueca N, et al. Evaluation of eight differentbioinformatics tools to predict viral tropism in different human immunodeficiencyvirus type 1 subtypes. J Clin Microbiol 2008; 46:887-891.
38. Thielen A, Sichtig N, Braun P, et al. Performance of genotypic coreceptormeasurement using geno2pheno[coreceptor] in B- and non-B HIV subtypesin a large cohort of therapy-experienced patients in Germany. In: 7th EuropeanHIV Drug Resistance Workshop; Stockholm, Sweden; 2009 March 25-27.
39. Delgado E, Ferna'ndez-Garci'a A, Vega Y, et al. Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes. J Antimicrob Chemother 2012; 67:25-31.
40. JensenMA, CoetzerM, van't Wout AB, et al. A reliable phenotype predictor forhuman immunodeficiency virus type 1 subtype C based on envelope V3sequences. J Virol 2006; 80:4698-4704.
41. Raymond S, Delobel P, Mavigner M, et al. Prediction of HIV type 1 subtype Ctropism by genotypic algorithms built from subtype B viruses. J Acquir ImmuneDefic Syndr 2010; 53:167-175.
42. Esbjornsson J, Mansson F, Martinez-Arias W, et al. Frequent CXCR4 tropismof HIV-1 subtype A and CRF02-AG during late-stage disease: Indication ofan evolving epidemic in West Africa. Retrovirology 2010; 7:23.
43. Raymond S, Delobel P, Mavigner M, et al. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 2009;47:2292-2294.
44. Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: High prevalence of CXCR4 tropismand heterogeneous composition of viral populations. J Virol 2007; 81:7885-7893.
45. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptoruse, disease stage, and HIV-1 subtypes A and D: Results from a rural Ugandancohort. J Acquir Immune Defic Syndr 2007; 45:28-33.
46. Raymond S, Delobel P, Chaix ML, et al. Genotypic prediction of HIV-1 subtypeD tropism. Retrovirology 2011; 8:56.
47. Sa'nchez V, MasiáM, Robledano C, et al. Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofilecoreceptor tropism assay. J Clin Microbiol 2010; 48:4135-4139.
48. Prosperi MCF, Bracciale L, Fabbiani M, et al. Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 2010; 7:56.
49. Vandekerckhove L, Verhofstede C, Demecheleer E, et al. Comparison of phenotypic and genotypic tropism determination in triple-class-experiencedHIV patients eligible for maraviroc treatment. J Antimicrob Chemother 2011; 66:265-272
50. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: A retrospective analysis using screening samples from the A4001029and MOTIVATE studies. AIDS 2010; 24:2517-2525.
51. Groenink M, Andeweg AC, Fouchier RA, et al. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: Evidence for in vivo recombination and determinants of cytotropismoutside the V3 domain. J Virol 1992; 66:6175-6180.
52. Groenink M, Fouchier RA, Broersen S, et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993; 260:1513-1516.
53. Huang W, Toma J, Fransen S, et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 2008; 82:5584-5593.
54. Thielen A, Sichtig N, Kaiser R, et al. Improved prediction of HIV-1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis 2010; 202:1435-1443.
55. Huang W, Toma J, Stawiski E, et al. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retr 2009; 25:795- 802.
56. Moore JP, Kuritzkes DR. A piece de resistance: How HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009; 4:118-124.
57. Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361:212-228.
58. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371.
59. Delobel P, Raymond S, Mavigner M, et al. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance tomaraviroc. AIDS 2010; 24:1382-1384.
60. Mori J, Mosley M, Lewis M, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2. In: 16th International HIV Drug Resistance Workshop, Barbados; 2007 June 12-16.
61. Lewis J, Simpson P, Delogne C, et al. Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-experienced Patients Enrolled into the MOTIVATEStudies and Who Received Maraviroc Optimized Background Therapy. In: 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA; 2010 February 16-19.
62. Ogert RA, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 coreceptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology2008; 373:387-399.